CTXR: Citius Pharmaceuticals Inc. Stocks News on November 27, 2025

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

CTXR

PR Newswire

6 days ago

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

CTXR

Simply Wall St.

15 days ago

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Is Expected To Breakeven In The Near Future

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

CTXR

PR Newswire

a month ago

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

CTXR

PR Newswire

a month ago

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

CTXR

PR Newswire

a month ago

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

CTXR

MT Newswires

a month ago

Citius Oncology Says Commercialization Deal Signed With Eversana for Planned Launch of Lymphir in Q4

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

CTXR

PR Newswire

a month ago

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTXR

PR Newswire

3 months ago

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTXR

PR Newswire

3 months ago

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

CTXR

PR Newswire

5 months ago

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

CTXR

PR Newswire

5 months ago

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

CTXR

MT Newswires

6 months ago

Top Midday Decliners

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

CTXR

PR Newswire

6 months ago

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

CTXR

MT Newswires

6 months ago

Citius Oncology Signs US Distribution Deal With Cardinal Health for Lymphir

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

CTXR

PR Newswire

6 months ago

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

CTXR

PR Newswire

6 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTXR

PR Newswire

7 months ago

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

CTXR

PR Newswire

8 months ago

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTXR

PR Newswire

10 months ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

CTXR

MT Newswires

a year ago

Sector Update: Health Care Stocks Advance Late Afternoon

CTXR

MT Newswires

a year ago

Sector Update: Health Care

CTXR

MT Newswires

a year ago

Citius Pharmaceuticals Shares Rise After Announcing Plans for Lymphir Launch

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Citius Oncology to explore strategic alternatives

CTXR

TipRanks

a year ago

Citius Oncology to explore strategic alternatives

CTXR

MT Newswires

a year ago

Sector Update: Health Care Stocks Decline Late Afternoon

CTXR

MT Newswires

a year ago

Correction: Citius Oncology Retains Jefferies to Consider Strategic Alternatives

CTXR

MT Newswires

a year ago

Citius Oncology Retains Jeffries to Consider Strategic Alternatives

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

CTXR

PR Newswire

a year ago

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital

CTXR

TipRanks

a year ago

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

CTXR

The Fly

a year ago

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

Citius Pharma Reports 2024 Financial Results and Business Update

CTXR

TipRanks

a year ago

Citius Pharma Reports 2024 Financial Results and Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

CTXR

Simply Wall St.

a year ago

Market Sentiment Around Loss-Making Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

CTXR

MT Newswires

a year ago

Citius Pharmaceuticals Launching 1-for-25 Reverse Stock Split

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

CTXR

MT Newswires

a year ago

Citius Pharmaceuticals to Raise $3 Million via Offering; Shares Drop

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

CTXR

MT Newswires

a year ago

Citius Shares Jump After Reporting Positive Results From Early Study of Potential Cancer Treatment

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

Sidoti Events, LLC's Virtual August Micro-Cap Conference

CTXR

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual August Micro-Cap Conference

Citius merges oncology subsidiary with TenX Keane

CTXR

Pharmaceutical Technology

a year ago

Citius merges oncology subsidiary with TenX Keane

CTXR

MT Newswires

a year ago

Citius Pharmaceuticals Completes Merger of Oncology Subsidiary With Blank Check Firm TenX Keane

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

CTXR

GlobeNewswire

a year ago

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection

CTXR

Benzinga

a year ago

Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection

$Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma$

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

CTXR

MT Newswires

a year ago

TenX Keane's Shareholders Approve Merger With Citius Oncology Unit

TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

CTXR

GlobeNewswire

a year ago

TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

CTXR

Simply Wall St.

a year ago

When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Turn A Profit?

Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)

CTXR

Newsfile

a year ago

Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)

Analysts Hunt for Undervalued Biotech Stocks

CTXR

Newsfile

a year ago

Analysts Hunt for Undervalued Biotech Stocks

Bloodstream Infections - From Threats to Solutions

CTXR

Newsfile

a year ago

Bloodstream Infections - From Threats to Solutions

Biopharma Stocks Transformative Innovation for the Future of Health

CTXR

Newsfile

a year ago

Biopharma Stocks Transformative Innovation for the Future of Health

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates

2 Biotech Stocks With Big FDA Decisions Approaching – Here’s What Analysts Expect

CTXR

TipRanks

a year ago

2 Biotech Stocks With Big FDA Decisions Approaching – Here’s What Analysts Expect

Sidoti Events, LLC's Virtual June Small-Cap Conference

CTXR

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual June Small-Cap Conference

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

CTXR

PR Newswire

a year ago

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

CTXR

PR Newswire

2 years ago

Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update

CTXR

PR Newswire

2 years ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences

CTXR

PR Newswire

2 years ago

Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

CTXR

PR Newswire

2 years ago

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

CTXR

MT Newswires

2 years ago

Citius Pharmaceuticals Launches $15 Million Offering

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

CTXR

PR Newswire

2 years ago

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

CTXR

PR Newswire

2 years ago

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

CTXR

PR Newswire

2 years ago

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

$Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma$

CTXR

PR Newswire

2 years ago

Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Sidoti Events, LLC's Virtual March Small-Cap Conference

CTXR

ACCESSWIRE

2 years ago

Sidoti Events, LLC's Virtual March Small-Cap Conference

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program

CTXR

PR Newswire

2 years ago

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

CTXR

PR Newswire

2 years ago

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences

CTXR

PR Newswire

2 years ago

Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences

CTXR

GuruFocus.com

2 years ago

Citius Pharmaceuticals Inc (CTXR) Reports Q1 2024 Financials and Progress in Clinical Trials

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

CTXR

PR Newswire

2 years ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

$Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma$